Literature DB >> 25787214

Prevalence of isolated systolic hypertension (ISH) in Slovene hypertensive patients: insights from the "Quality of Healthcare in Slovenia" project.

Marjetka Pal1, Polonca Ferk2, Brane Leskošek3, Ivan Krajnc4, Marjan Pajntar5.   

Abstract

OBJECTIVES: The aim of the present study was mainly to evaluate age- and gender-dependent isolated systolic hypertension (ISH) prevalence before and during antihypertensive treatment, and to evaluate pulse pressure (PP) distributions during antihypertensive treatment in almost 20,000 Slovene hypertensive patients.
METHODS: The study was conducted as part of the "Quality of Healthcare in Slovenia" project, in agreement with the National Medical Ethics Committee of the Republic of Slovenia. Appropriate statistical analyses and evaluations were performed.
RESULTS: The prevalence of ISH before the treatment was 19.6 % (17.0 % for men and 21.4 % for women) and it was significantly (p < 0.001) higher during the treatment (29.6 %; 26.4 % for men and 31.9 % for women). The mean PP before the treatment for the whole study patient sample was (71.2 ± 16.9) mmHg and was significantly (p < 0.001) reduced during the treatment to (57.4 ± 12.5) mmHg.
CONCLUSION: With regard to high ISH in treated Slovene hypertensive patients, quality of ISH control may not be optimal and should be improved. On the other hand, the adequate arterial hypertension (AH) control (systolic blood pressure (SBP) < 140 mmHg and diastolic blood pressure (DBP) < 90 mmHg) was achieved in 55.6 % of patients. Our observations may have useful therapeutic implications in the management of AH, particularly ISH in the elderly.

Entities:  

Keywords:  Arterial hypertension; Epidemiology; Isolated systolic hypertension; Pulse pressure; Quality of arterial hypertension treatment

Mesh:

Substances:

Year:  2015        PMID: 25787214     DOI: 10.1007/s00508-015-0765-z

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  17 in total

Review 1.  Pulse pressure, arterial stiffness, and drug treatment of hypertension.

Authors:  L M Van Bortel; H A Struijker-Boudier; M E Safar
Journal:  Hypertension       Date:  2001-10       Impact factor: 10.190

2.  Pulse pressure and mortality in older people.

Authors:  R J Glynn; C U Chae; J M Guralnik; J O Taylor; C H Hennekens
Journal:  Arch Intern Med       Date:  2000-10-09

Review 3.  Clinical practice. Isolated systolic hypertension in the elderly.

Authors:  Aram V Chobanian
Journal:  N Engl J Med       Date:  2007-08-23       Impact factor: 91.245

4.  Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP).

Authors:  H M Perry; B R Davis; T R Price; W B Applegate; W S Fields; J M Guralnik; L Kuller; S Pressel; J Stamler; J L Probstfield
Journal:  JAMA       Date:  2000-07-26       Impact factor: 56.272

5.  Knowledge and acceptance of hypertension guidelines in clinical practice: experience from Slovenia.

Authors:  Marija Petek Ster; Janko Kersnik
Journal:  Wien Klin Wochenschr       Date:  2005-08       Impact factor: 1.704

Review 6.  Systolic hypertension in older persons.

Authors:  Sarwat I Chaudhry; Harlan M Krumholz; JoAnne Micale Foody
Journal:  JAMA       Date:  2004-09-01       Impact factor: 56.272

7.  Sex differences in pulse pressure trends with age are cross-cultural.

Authors:  Joan H Skurnick; Mordechay Aladjem; Abraham Aviv
Journal:  Hypertension       Date:  2009-11-16       Impact factor: 10.190

8.  Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study.

Authors:  W B Kannel; P A Wolf; D L McGee; T R Dawber; P McNamara; W P Castelli
Journal:  JAMA       Date:  1981-03-27       Impact factor: 56.272

Review 9.  Management of hypertension in the elderly patient.

Authors:  Gordon Stewart Stokes
Journal:  Clin Interv Aging       Date:  2009-10-12       Impact factor: 4.458

10.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood
Journal:  Eur Heart J       Date:  2013-06-14       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.